title: [Pharmacotherapy in complex treatment of ulcerous stenosis].
abstract: The authors present results of the examination and treatment of 64 patients with ulcer disease complicated by stenosis (27 patients had compensated stenosis, 33--subcompensated and 4 patients--decompensated stenosis). The investigation of the dynamics of main pathophysiological disorders and specific action of medicinal preparations has revealed the causes of ineffectiveness of standard antiulcerous therapy. The principles of conservative treatment of ulcer disease with stenosis are developed. The proposed method of treatment resulted in cicatrization of the ulcer, disappearance of the inflammatory edema of the mucosa, reestablishment of patency of the pyloro-duodenal canal and stable remission of the disease in 58 patients (followed up during the period from 6 months till 3 years). Only 6 (9.4%) out of 64 patients were operated upon (2--with decompensated and 4 with subcompensated stenosis). The results obtained show that it is necessary to determine the indications to operations in patients with ulcerous stenosis after complex conservative therapy and the reassessment of the degree of evacuatory disorders.
authors.forename: N V
authors.initials: NV
authors.lastname: Rukhliada
authors.forename: V E
authors.initials: VE
authors.lastname: Nazarov
authors.forename: I A
authors.initials: IA
authors.lastname: Ermolaev
mesh_terms: D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use; D000863:Antacids / Q000008:administration & dosage / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002927:Cimetidine / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use; D009853:Omeprazole / Q000008:administration & dosage / Q000627:therapeutic use; D011707:Pyloric Stenosis / Q000150:complications / Q000209:etiology* / Q000503:physiopathology; D011899:Ranitidine / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000863:Antacids; D000890:Anti-Infective Agents; D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D006635:Histamine H2 Antagonists; D008795:Metronidazole; D002927:Cimetidine; D000658:Amoxicillin; D011899:Ranitidine; D009853:Omeprazole